(Q37061134)

18 August 2017

1 reference

title

COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs (English)

1 reference

18 August 2017

0 references

1 reference

1

Timothy D Warner

1 reference

18 August 2017

Jane A Mitchell

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

371

1 reference

18 August 2017

issue

9608

1 reference

18 August 2017

page(s)

270-273

1 reference

Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Cardiovascular effects of the cyclooxygenase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

NSAIDs, coxibs, and the intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Balancing prostanoid activity in the human vascular system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Nomenclature for COX-2 inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear str

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Comparison of the effect of intravenous ketoprofen, ketorolac and diclofenac on platelet function in volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Minimising the adverse effects of ketorolac

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960137-3

7 January 2021

10.1016/S0140-6736(08)60137-3

Identifiers

DOI

1 reference

18 August 2017

1 reference